Newsweek: The New Era of Life Sciences 2024

May 15, 2024 – FACIT President discusses early-stage investing in Canada in an interview with Newsweek’s Investment Reports and appeared in The New Era of Life Sciences 2024. FACIT is an innovative organization focused on bridging the gap between cancer research breakthroughs and their commercialization, thereby accelerating the journey of scientific discoveries from the laboratory to the marketplace.

Read More from Newsweek: The New Era of Life Sciences 2024

FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca

March 20, 2024 – FACIT’s portfolio company Fusion Pharmaceuticals is being acquired by AstraZeneca for a total transaction value of up to $2.4 billion. Congratulations to the team at Fusion for building value over the last decade that will have a lasting impact on patients with cancer and the Ontario economy.

Read More from FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca

FACIT portfolio company Tenomix secures an all-Canadian investment round for colorectal cancer diagnostic

March 1, 2024 – FACIT congratulates London, Ontario based Tenomix Inc. (“Tenomix”) on successfully reaching a key milestone in closing its latest financing round to help propel the medtech start-up. Tenomix’s bench-top device will save time and costs by automating the process of lymph node identification in resected tissue while providing more accurate cancer staging for better patient care.

Read More from FACIT portfolio company Tenomix secures an all-Canadian investment round for colorectal cancer diagnostic

cTRL Therapeutics announces new Chief Executive Officer to continue advancing its novel immune cell therapy

November 2, 2023 – cTRL Therapeutics (“cTRL”), a FACIT co-founded and financed company developing novel tumour cell therapies for patients living with cancer, welcomes industry veteran Derrell D. Porter, M.D., as Chief Executive Officer.

Read More from cTRL Therapeutics announces new Chief Executive Officer to continue advancing its novel immune cell therapy

FACIT applauds quizartinib approval: a success for leukemia patients and Canadian cancer research translation

July 24, 2023 – The U.S. FDA announced the approval of quizartinib, an important new therapy for patients with leukemia. This global effort to impact patients in need is to be celebrated while recognizing the contributions from across the Canadian health R&D ecosystem to reach this significant milestone that will now make a difference for patients.

Read More from FACIT applauds quizartinib approval: a success for leukemia patients and Canadian cancer research translation

FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies

April 25, 2023 – Emerging from stealth mode, Radiant’s financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer.

Read More from FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies

CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.

Read More from CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

FACIT backs made-in-Ontario data science and medtech innovations through Prospects Oncology Fund

June 23, 2020 – June 23, 2020 – FACIT’s investments strategically address the seed-stage gap experienced by Ontario’s life sciences sector, fueling promising cancer breakthroughs towards a value inflection point and helping local start-ups establish and anchor jobs in the province.

Read More from FACIT backs made-in-Ontario data science and medtech innovations through Prospects Oncology Fund